Infinium Pharmachem Limited has commissioned a new manufacturing facility for contrast media raw materials at GIDC Sojitra in Anand district, Gujarat, effective 16 January 2026. The commissioning marks the company’s entry into the contrast media value chain and is aligned with its strategy to expand into higher-value, specialised iodine chemistry products.
The new unit represents a step in its forward integration plans and leverages Infinium Pharmachem’s existing capabilities in iodine-based chemistry. The facility is intended to support the production of raw materials used in contrast media, which are applied in pharmaceutical and diagnostic imaging applications.
The company said the contrast media segment is expected to emerge as a significant growth driver over the medium term. Over the next three years, Infinium Pharmachem is targeting annual revenue of approximately INR 1 billion from this segment. The company anticipates an earnings before interest, tax, depreciation and amortisation (EBITDA) margin of around 30 percent from contrast media-related products, which is expected to lift its blended EBITDA margin to about 20 percent.
The expansion is positioned as a move towards value-added offerings within the healthcare supply chain. By entering contrast media raw materials manufacturing, Infinium Pharmachem aims to broaden its end-use exposure across pharmaceutical, diagnostic imaging and healthcare markets, while reducing reliance on lower-margin segments.
The company did not disclose the capital expenditure incurred for the new facility or its installed production capacity. It also did not provide a detailed timeline for ramp-up or customer onboarding from the newly commissioned unit.
Infinium Pharmachem Limited is headquartered in Anand, Gujarat, and is listed on the National Stock Exchange of India under the symbol INFINIUM. The company manufactures iodine derivatives, pharmaceutical intermediates and active pharmaceutical ingredients. It also undertakes contract research and manufacturing services, providing customised and confidential solutions to clients across the pharmaceutical sector.
